Danique R. M. Vlaskamp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Danique R. M. Vlaskamp has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Conny M. A. van Ravenswaaij-Arts
University of Groningen, University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands
4 shared publications - Petra M. C. Callenbach
University of Groningen, University Medical Centre Groningen, Department of Neurology, Groningen, The Netherlands
3 shared publications - Ingrid Eileen Scheffer
Epilepsy Research Centre University of Melbourne, Austin Health Heidelberg Victoria Australia
2 shared publications - Lucia A. A. Giannini
Department of Neurology, Alzheimer Center Erasmus MC Erasmus University Medical Center Rotterdam The Netherlands
2 shared publications - Oebele F. Brouwer
Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications Patrick Rump
University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 1 May 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 32, 128-135
Changes in empowerment and anxiety of patients and parents during genetic counselling for epilepsy
- 1 May 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 32, 128-135
Open AccessChanges in empowerment and anxiety of patients and parents during genetic counselling for epilepsy
- Open Access
- 1 April 2019
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 62 (4) , 265-269
PRRT2-related phenotypes in patients with a 16p11.2 deletion
- 1 April 2019
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 62 (4) , 265-269
Open AccessPRRT2-related phenotypes in patients with a 16p11.2 deletion
Schizophrenia is a later‐onset feature ofPCDH19Girls Clustering Epilepsy
Summary: Objective: To investigate the occurrence of psychosis and serious behavioral problems in females with protocadherin 19 gene (PCDH19) pathogenic variants.Methods: We evaluated whether psychosis and serious behavioral problems had occurred in 60 females (age 2‐75 years) withPCDH19pathogenic variants belonging to 35 families. Patients were identified from epilepsy genetics databases in Australia, New Zealand, theUnited States,and Canada. Neurologic and psychiatric disorders were diagnosed using standard methods.Results: Eight of 60 females (13%) from 7 families developed a psychotic disorder: schizophrenia (6), schizoaffective disorder (1), or an unspecified psychotic disorder (1). Median age at onset of psychotic symptoms was 21 years (range 11‐28 years). In our cohort of 39 females aged 11 years or older, 8 (21%) developed a psychotic disorder. Seven had ongoing seizures at onset of psychosis, with 2 continuing to have seizures when psychosis recurred. Psychotic disorders occurred in the setting of mild (4), moderate (2), or severe (1) intellectual disability, or normal intellect (1). Preexisting behavioral problems occurred in 4 patients, and autism spectrum disorder in 3. Two additional females (3%) had psychotic features with other conditions: an adolescent had recurrent episodes of postictal psychosis, and a 75‐year‐old woman had major depression with psychotic features. A further 3 adolescents (5%) with moderate to severe intellectual disability had onset of severe behavioral disturbance, or significant worsening.Significance: We identify that psychotic disorders, including schizophrenia, are a later‐onset manifestation ofPCDH19Girls Clustering Epilepsy. Affected girls and women should be carefully monitored for later‐onset psychiatric disorders.
Schizophrenia is a later‐onset feature ofPCDH19Girls Clustering Epilepsy
Summary: Objective: To investigate the occurrence of psychosis and serious behavioral problems in females with protocadherin 19 gene (PCDH19) pathogenic variants.Methods: We evaluated whether psychosis and serious behavioral problems had occurred in 60 females (age 2‐75 years) withPCDH19pathogenic variants belonging to 35 families. Patients were identified from epilepsy genetics databases in Australia, New Zealand, theUnited States,and Canada. Neurologic and psychiatric disorders were diagnosed using standard methods.Results: Eight of 60 females (13%) from 7 families developed a psychotic disorder: schizophrenia (6), schizoaffective disorder (1), or an unspecified psychotic disorder (1). Median age at onset of psychotic symptoms was 21 years (range 11‐28 years). In our cohort of 39 females aged 11 years or older, 8 (21%) developed a psychotic disorder. Seven had ongoing seizures at onset of psychosis, with 2 continuing to have seizures when psychosis recurred. Psychotic disorders occurred in the setting of mild (4), moderate (2), or severe (1) intellectual disability, or normal intellect (1). Preexisting behavioral problems occurred in 4 patients, and autism spectrum disorder in 3. Two additional females (3%) had psychotic features with other conditions: an adolescent had recurrent episodes of postictal psychosis, and a 75‐year‐old woman had major depression with psychotic features. A further 3 adolescents (5%) with moderate to severe intellectual disability had onset of severe behavioral disturbance, or significant worsening.Significance: We identify that psychotic disorders, including schizophrenia, are a later‐onset manifestation ofPCDH19Girls Clustering Epilepsy. Affected girls and women should be carefully monitored for later‐onset psychiatric disorders.
- Top Cited PapersOpen Access
- 8 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (2) , e96-e107
SYNGAP1 encephalopathy
Objective To delineate the epileptology, a key part of the SYNGAP1 phenotypic spectrum, in a large patient cohort. Methods Patients were recruited via investigators9 practices or social media. We included patients with (likely) pathogenic SYNGAP1 variants or chromosome 6p21.32 microdeletions incorporating SYNGAP1. We analyzed patients9 phenotypes using a standardized epilepsy questionnaire, medical records, EEG, MRI, and seizure videos. Results We included 57 patients (53% male, median age 8 years) with SYNGAP1 mutations (n = 53) or microdeletions (n = 4). Of the 57 patients, 56 had epilepsy: generalized in 55, with focal seizures in 7 and infantile spasms in 1. Median seizure onset age was 2 years. A novel type of drop attack was identified comprising eyelid myoclonia evolving to a myoclonic-atonic (n = 5) or atonic (n = 8) seizure. Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%. Developmental delay preceded seizure onset in 54 of 56 (96%) patients for whom early developmental history was available. Developmental plateauing or regression occurred with seizures in 56 in the context of a developmental and epileptic encephalopathy (DEE). Fifty-five of 57 patients had intellectual disability, which was moderate to severe in 50. Other common features included behavioral problems (73%); high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%). Conclusions SYNGAP1 mutations cause a generalized DEE with a distinctive syndrome combining epilepsy with eyelid myoclonia with absences and myoclonic-atonic seizures, as well as a predilection to seizures triggered by eating.
- 8 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (2) , e96-e107
Top Cited PapersOpen AccessSYNGAP1 encephalopathy
Objective To delineate the epileptology, a key part of the SYNGAP1 phenotypic spectrum, in a large patient cohort. Methods Patients were recruited via investigators9 practices or social media. We included patients with (likely) pathogenic SYNGAP1 variants or chromosome 6p21.32 microdeletions incorporating SYNGAP1. We analyzed patients9 phenotypes using a standardized epilepsy questionnaire, medical records, EEG, MRI, and seizure videos. Results We included 57 patients (53% male, median age 8 years) with SYNGAP1 mutations (n = 53) or microdeletions (n = 4). Of the 57 patients, 56 had epilepsy: generalized in 55, with focal seizures in 7 and infantile spasms in 1. Median seizure onset age was 2 years. A novel type of drop attack was identified comprising eyelid myoclonia evolving to a myoclonic-atonic (n = 5) or atonic (n = 8) seizure. Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%. Developmental delay preceded seizure onset in 54 of 56 (96%) patients for whom early developmental history was available. Developmental plateauing or regression occurred with seizures in 56 in the context of a developmental and epileptic encephalopathy (DEE). Fifty-five of 57 patients had intellectual disability, which was moderate to severe in 50. Other common features included behavioral problems (73%); high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%). Conclusions SYNGAP1 mutations cause a generalized DEE with a distinctive syndrome combining epilepsy with eyelid myoclonia with absences and myoclonic-atonic seizures, as well as a predilection to seizures triggered by eating.
- Open Access
- 8 May 2017
- Published by Wiley in Epilepsia Open
- Vol. 2 (2) , 244-254
Copy number variation in a hospital‐based cohort of children with epilepsy
Summary: Objective: To evaluate the diagnostic yield of microarray analysis in a hospital‐based cohort of children with seizures and to identify novel candidate genes and susceptibility loci for epilepsy.Methods: Of all children who presented with their first seizure in the University Medical Center Groningen (January 2000 through May 2013) (n = 1,368), we included 226 (17%) children who underwent microarray analysis before June 2014. All 226 children had a definite diagnosis of epilepsy. All their copy number variants (CNVs) on chromosomes 1–22 and X that contain protein‐coding genes and have a prevalence of MYT1L, UNC5D, SCN4B, and NRXN3.Significance: The 11% yield in our hospital‐based cohort underscores the importance of microarray analysis in diagnostic evaluation of children with epilepsy.
- 8 May 2017
- Published by Wiley in Epilepsia Open
- Vol. 2 (2) , 244-254
Open AccessCopy number variation in a hospital‐based cohort of children with epilepsy
Summary: Objective: To evaluate the diagnostic yield of microarray analysis in a hospital‐based cohort of children with seizures and to identify novel candidate genes and susceptibility loci for epilepsy.Methods: Of all children who presented with their first seizure in the University Medical Center Groningen (January 2000 through May 2013) (n = 1,368), we included 226 (17%) children who underwent microarray analysis before June 2014. All 226 children had a definite diagnosis of epilepsy. All their copy number variants (CNVs) on chromosomes 1–22 and X that contain protein‐coding genes and have a prevalence of MYT1L, UNC5D, SCN4B, and NRXN3.Significance: The 11% yield in our hospital‐based cohort underscores the importance of microarray analysis in diagnostic evaluation of children with epilepsy.